HUTCHMED (China) Analyst Ratings
HUTCHMED (China) Analyst Ratings
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a upgraded with a price target of $20.00 to $22.10. The current price HUTCHMED (China) (HCM) is trading at is $18.24, which is out of the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/24/2023 | 21.16% | Deutsche Bank | $20 → $22.1 | Upgrades | Hold → Buy |
| 11/10/2023 | -6.8% | Goldman Sachs | $15 → $17 | Maintains | Neutral |
| 09/05/2023 | 174.12% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 07/24/2023 | 174.12% | Cantor Fitzgerald | → $50 | Reiterates | Overweight → Overweight |
| 08/09/2022 | -12.28% | Goldman Sachs | $14 → $16 | Maintains | Neutral |
| 08/02/2022 | -23.25% | Goldman Sachs | $16 → $14 | Maintains | Neutral |
| 09/22/2021 | 152.19% | Goldman Sachs | → $46 | Downgrades | Buy → Neutral |
| 08/03/2021 | 185.09% | Jefferies | → $52 | Initiates Coverage On | → Buy |
| 03/13/2020 | — | Cantor Fitzgerald | Initiates Coverage On | → Overweight | |
| 02/20/2020 | 108.33% | Goldman Sachs | → $38 | Initiates Coverage On | → Buy |
| 11/19/2019 | — | CLSA | Initiates Coverage On | → Buy | |
| 10/23/2019 | — | B of A Securities | Reinstates | → Buy | |
| 03/04/2019 | — | Deutsche Bank | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/24/2023 | 21.16% | 德意志银行 | 20 美元 → 22.1 美元 | 升级 | 持有 → 买入 |
| 11/10/2023 | -6.8% | 高盛 | 15 美元 → 17 美元 | 维护 | 中立 |
| 09/05/2023 | 174.12% | 坎托·菲茨杰拉德 | → 50 美元 | 重申 | 超重 → 超重 |
| 2023 年 7 月 24 日 | 174.12% | 坎托·菲茨杰拉德 | → 50 美元 | 重申 | 超重 → 超重 |
| 08/09/2022 | -12.28% | 高盛 | 14 美元 → 16 美元 | 维护 | 中立 |
| 08/02/2022 | -23.25% | 高盛 | 16 美元 → 14 美元 | 维护 | 中立 |
| 2021 年 9 月 22 日 | 152.19% | 高盛 | → 46 美元 | 降级 | 买入 → 中性 |
| 08/03/2021 | 185.09% | 杰富瑞集团 | → 52 美元 | 启动覆盖范围开启 | → 购买 |
| 03/13/2020 | — | 坎托·菲茨杰拉德 | 启动覆盖范围开启 | → 超重 | |
| 02/20/2020 | 108.33% | 高盛 | → 38 美元 | 启动覆盖范围开启 | → 购买 |
| 11/19/2019 | — | CLSA | 启动覆盖范围开启 | → 购买 | |
| 2019 年 10 月 23 日 | — | B of A 类证券 | 恢复 | → 购买 | |
| 03/04/2019 | — | 德意志银行 | 启动覆盖范围开启 | → 购买 |
What is the target price for HUTCHMED (China) (HCM)?
和黄医药（中国）（HCM）的目标价格是多少？
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Deutsche Bank on November 24, 2023. The analyst firm set a price target for $22.10 expecting HCM to rise to within 12 months (a possible 21.16% upside). 4 analyst firms have reported ratings in the last year.
德意志银行于2023年11月24日公布了和黄医药（中国）（纳斯达克股票代码：HCM）的最新目标股价。该分析公司将目标股价定为22.10美元，预计HCM将在12个月内上涨至21.16％（可能上涨21.16％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
和黄医药（中国）（HCM）的最新分析师评级是多少？
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Deutsche Bank, and HUTCHMED (China) upgraded their buy rating.
和黄医药（中国）（纳斯达克股票代码：HCM）的最新分析师评级由德意志银行提供，和黄医药（中国）上调了买入评级。
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
和黄医药（中国）（HCM）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on November 24, 2023 so you should expect the next rating to be made available sometime around November 24, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与和黄医药（中国）的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。和黄医药（中国）的最新评级是在2023年11月24日公布的，因此您应该预计下一个评级将在2024年11月24日左右公布。
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
和黄医药（中国）（HCM）的分析师评级是否正确？
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a upgraded with a price target of $20.00 to $22.10. The current price HUTCHMED (China) (HCM) is trading at is $18.24, which is out of the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的和黄医药（中国）（HCM）评级已上调，目标股价为20.00美元，至22.10美元。和黄医药（中国）（HCM）目前的交易价格为18.24美元，超出了分析师的预期区间。
